Loading…
.jpg?rev=43e9c92a6040483284de869121a02f4b&hash=D6DCFE99E7B19D405621E3217C5D5254)
Misonix, a provider of minimally invasive therapeutic ultrasonic technologies, has been acquired by Bioventus. Misonix stockholders received either 1.6839 shares of Bioventus class A common stock or $28.00 in cash per share.
“Misonix is a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes and Bioventus is a global leader in innovations for active healing.”jonesday.com
Summarized from public sources; check the original articles before acting on it.